Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis Read more
Biocon Biologics finalises agreement for Bmab 1200 market entry in Europe, UK, Canada, and Japan Read more
Dr Reddy’s receives positive CHMP opinion for biosimilar Rituximab candidate in European markets Read more